Optimizing antenatal corticosteroid therapy

Matthew W. Kemp, Augusto F. Schmidt, Alan H. Jobe

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Treatment with antenatal corticosteroids (ACS) is standard of care for women at risk of preterm birth between 24 and 34 weeks’ gestation. ACS are increasingly used for other indications, including threated or indicated late preterm birth, elective cesarean, and in at-risk pregnancies for periviable gestations. However, the various drugs and doses being used worldwide have not been rigorously evaluated to optimize clinical responses and to minimize potential risks. Translational research in animal models indicate that a constant, low concentration fetal exposure to ACS is sufficient for lung maturation, resulting in lower fetal exposures. Clinical trials to develop dosing strategies with inexpensive and widely available drugs could promote greater use in low resource environments. “Even the best proven interventions must be evaluated continually through research for their safety, effectiveness, efficacy, accessibility and quality,” Declaration of Helsinki [1].

Original languageEnglish
Pages (from-to)176-181
Number of pages6
JournalSeminars in Fetal and Neonatal Medicine
Volume24
Issue number3
DOIs
Publication statusPublished - 1 Jun 2019

Fingerprint

Adrenal Cortex Hormones
Premature Birth
Pregnancy
Helsinki Declaration
Translational Medical Research
Standard of Care
Pharmaceutical Preparations
Therapeutics
Animal Models
Clinical Trials
Safety
Lung
Research

Cite this

Kemp, Matthew W. ; Schmidt, Augusto F. ; Jobe, Alan H. / Optimizing antenatal corticosteroid therapy. In: Seminars in Fetal and Neonatal Medicine. 2019 ; Vol. 24, No. 3. pp. 176-181.
@article{e24d5e8638524cc7a03a272bf5983497,
title = "Optimizing antenatal corticosteroid therapy",
abstract = "Treatment with antenatal corticosteroids (ACS) is standard of care for women at risk of preterm birth between 24 and 34 weeks’ gestation. ACS are increasingly used for other indications, including threated or indicated late preterm birth, elective cesarean, and in at-risk pregnancies for periviable gestations. However, the various drugs and doses being used worldwide have not been rigorously evaluated to optimize clinical responses and to minimize potential risks. Translational research in animal models indicate that a constant, low concentration fetal exposure to ACS is sufficient for lung maturation, resulting in lower fetal exposures. Clinical trials to develop dosing strategies with inexpensive and widely available drugs could promote greater use in low resource environments. “Even the best proven interventions must be evaluated continually through research for their safety, effectiveness, efficacy, accessibility and quality,” Declaration of Helsinki [1].",
keywords = "Betamethasone, Dexamethasone, Maturation, Pharmacology, Prematurity",
author = "Kemp, {Matthew W.} and Schmidt, {Augusto F.} and Jobe, {Alan H.}",
year = "2019",
month = "6",
day = "1",
doi = "10.1016/j.siny.2019.05.003",
language = "English",
volume = "24",
pages = "176--181",
journal = "Seminars in Fetal & Neonatal Medicine",
issn = "1084-2756",
publisher = "Elsevier",
number = "3",

}

Optimizing antenatal corticosteroid therapy. / Kemp, Matthew W.; Schmidt, Augusto F.; Jobe, Alan H.

In: Seminars in Fetal and Neonatal Medicine, Vol. 24, No. 3, 01.06.2019, p. 176-181.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Optimizing antenatal corticosteroid therapy

AU - Kemp, Matthew W.

AU - Schmidt, Augusto F.

AU - Jobe, Alan H.

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Treatment with antenatal corticosteroids (ACS) is standard of care for women at risk of preterm birth between 24 and 34 weeks’ gestation. ACS are increasingly used for other indications, including threated or indicated late preterm birth, elective cesarean, and in at-risk pregnancies for periviable gestations. However, the various drugs and doses being used worldwide have not been rigorously evaluated to optimize clinical responses and to minimize potential risks. Translational research in animal models indicate that a constant, low concentration fetal exposure to ACS is sufficient for lung maturation, resulting in lower fetal exposures. Clinical trials to develop dosing strategies with inexpensive and widely available drugs could promote greater use in low resource environments. “Even the best proven interventions must be evaluated continually through research for their safety, effectiveness, efficacy, accessibility and quality,” Declaration of Helsinki [1].

AB - Treatment with antenatal corticosteroids (ACS) is standard of care for women at risk of preterm birth between 24 and 34 weeks’ gestation. ACS are increasingly used for other indications, including threated or indicated late preterm birth, elective cesarean, and in at-risk pregnancies for periviable gestations. However, the various drugs and doses being used worldwide have not been rigorously evaluated to optimize clinical responses and to minimize potential risks. Translational research in animal models indicate that a constant, low concentration fetal exposure to ACS is sufficient for lung maturation, resulting in lower fetal exposures. Clinical trials to develop dosing strategies with inexpensive and widely available drugs could promote greater use in low resource environments. “Even the best proven interventions must be evaluated continually through research for their safety, effectiveness, efficacy, accessibility and quality,” Declaration of Helsinki [1].

KW - Betamethasone

KW - Dexamethasone

KW - Maturation

KW - Pharmacology

KW - Prematurity

UR - http://www.scopus.com/inward/record.url?scp=85065624770&partnerID=8YFLogxK

U2 - 10.1016/j.siny.2019.05.003

DO - 10.1016/j.siny.2019.05.003

M3 - Article

VL - 24

SP - 176

EP - 181

JO - Seminars in Fetal & Neonatal Medicine

JF - Seminars in Fetal & Neonatal Medicine

SN - 1084-2756

IS - 3

ER -